Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC). Survival of patients (pts) ...

Anal fistulas can be painful and persistent. Here’s what causes them and the best treatment options to manage or eliminate ...

The most common symptoms for colorectal cancer in younger patients are abdominal pain; unexplained weight loss; changes in the frequency, size or appearance of stools; and rectal bleeding ...

Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.